HRP20150849T1 - Farmaceutski pripravak zasnovan na lijeku za zaštitu jetre i prebiotiku, proizvodnja i njegova uporaba - Google Patents
Farmaceutski pripravak zasnovan na lijeku za zaštitu jetre i prebiotiku, proizvodnja i njegova uporaba Download PDFInfo
- Publication number
- HRP20150849T1 HRP20150849T1 HRP20150849TT HRP20150849T HRP20150849T1 HR P20150849 T1 HRP20150849 T1 HR P20150849T1 HR P20150849T T HRP20150849T T HR P20150849TT HR P20150849 T HRP20150849 T HR P20150849T HR P20150849 T1 HRP20150849 T1 HR P20150849T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- acids
- use according
- liver
- prebiotic
- Prior art date
Links
- 235000013406 prebiotics Nutrition 0.000 title claims 6
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 7
- 210000004185 liver Anatomy 0.000 claims 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 206010051914 Cholesterosis Diseases 0.000 claims 2
- 229920002261 Corn starch Polymers 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 206010067125 Liver injury Diseases 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 2
- 235000013539 calcium stearate Nutrition 0.000 claims 2
- 239000008116 calcium stearate Substances 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 239000008120 corn starch Substances 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 208000001130 gallstones Diseases 0.000 claims 2
- 231100000234 hepatic damage Toxicity 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 230000008818 liver damage Effects 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 239000002574 poison Substances 0.000 claims 2
- 231100000614 poison Toxicity 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 235000012239 silicon dioxide Nutrition 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000000454 talc Substances 0.000 claims 2
- 229910052623 talc Inorganic materials 0.000 claims 2
- 239000004408 titanium dioxide Substances 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 claims 1
- 108010007979 Glycocholic Acid Proteins 0.000 claims 1
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 claims 1
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 claims 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 239000003833 bile salt Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000001801 chenodeoxycholic acids Chemical class 0.000 claims 1
- 235000019416 cholic acid Nutrition 0.000 claims 1
- 239000002812 cholic acid derivative Substances 0.000 claims 1
- 150000001842 cholic acids Chemical class 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims 1
- 229940099347 glycocholic acid Drugs 0.000 claims 1
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims 1
- 229960000511 lactulose Drugs 0.000 claims 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims 1
- 150000002643 lithocholic acids Chemical class 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 1
- 229920001592 potato starch Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims 1
- 150000003674 ursodeoxycholic acids Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (8)
1. Farmaceutski pripravak za uporabu u liječenju i prevenciji recidiva bolesti jetre koje su izazvane poremećajima u metabolizmu lipida-kolesterola, te su bolesti odabrane iz skupine koju čine stanja žučnih kamenaca koja uglavnom uključuju kamenac zbog kolesterola, alkoholni i nealkoholni steatohepatitis, primarna bilijarna ciroza, kolesteroza žučnog mjehura, te oštećenja jetre inducirana lijekovima i otrovima, naznačen time da se farmaceutski pripravak uzima interno i ima kao aktivne sastojke lijek za zaštitu jetre odabran iz skupine koju čine kolne kiseline, kenodeoksikolne kiseline, deoksikolio kiseline, ursodeoksikolne kiseline, litokolne kiseline, tauroursodeoksikolne kiseline, glikodeoksikolne kiseline, taurokolne kiseline, glikokolne kiseline, te laktulozu kao prebiotik, koji su izabrani u učinkovitim dozama.
2. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time da se uzima interno kao dodatak prehrani.
3. Farmaceutski pripravak za uporabu prema zahtjevu 1 ili 2, naznačen time da kao lijek za zaštitu jetre, ima žučnu kiselinu ili žučnu sol i prebiotik u omjeru 1:2 do 1:250 masenoga udjela čiste tvari.
4. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time da kao lijek za zaštitu jetre, sadrži esencijalne fosfolipide odabrane iz skupine koju čine fosfatidil kolin, cefalin, te fosfatidil inozitol.
5. Farmaceutski pripravak za uporabu prema zahtjevu 1 ili 4, naznačen time da kao lijek za zaštitu jetre, sadrži esencijalne fosfolipide i prebiotik u omjeru od 1:0.1 do 1:100 masenoga udjela čiste tvari.
6. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time da dodatno sadrži mikrokristaliničnu celulozu, laktozu, kukuruzni škrob, sredstva za skrućivanje, hidroksipropil metilcelulozu, karboksimetilcelulozu, oksipropil metilcelulozu, oksipropil celulozu, njihove farmaceutski dopuštene soli, Ludipress, kalcijev stearat, magnezijev stearat, polisorbat, polivinilpirolidon, polietilen glikol, talk, titanijev dioksid, ili silicijev dioksid.
7. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time da se nalazi u obliku tableta, granula, peleta, praška, kapsula, suspenzija, pasta, sirupa, emulzija ili gelova, koji su namijenjeni za internu upotrebu u dozama, koje odgovaraju dozama 2 do 3 puta dnevno poznatih lijekova za zaštitu jetre i prebiotika.
8. Proizvodnja farmaceutskog pripravka prema zahtjevu 1 za liječenje bolesti jetre koje su odabrane iz skupine koju čine stanja žučnih kamenaca koja uglavnom uključuju kamenac zbog kolesterola, alkoholni i nealkoholni steatohepatitis, primarna bilijarna ciroza, kolesteroza žučnog mjehura, te oštećenja jetre inducirana lijekovima i otrovima, naznačena time da se aktivni sastojci - lijek za zaštitu jetre i prebiotik – koji se uzimaju u učinkovitim količinama, miješaju s mikrokristaliničnom celulozom, laktozom, kukuruznim škrobom, krumpirovim škrobom, hidroksipropil metilcelulozom, karboksimetilcelulozom, oksipropil metilcelulozom, oksipropil celulozom, s njihovim farmaceutski dopuštenim solima, Ludipress, kalcijevim stearatom, magnezijevim stearatom, polisorbatom, polivinilpirolidonom, polietilen glikolom, talkom, titanijevim dioksidom, ili silicijevim dioksidom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08873197.1A EP2266619B1 (de) | 2008-03-04 | 2008-03-04 | Pharmazeutische zusammensetzung auf basis eines leberschützenden mittels und eines präbiotischen mittels, ihre herstellung und verwendung |
| PCT/RU2008/000122 WO2009110816A1 (ru) | 2008-03-04 | 2008-03-04 | Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150849T1 true HRP20150849T1 (hr) | 2015-09-25 |
Family
ID=41056233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150849TT HRP20150849T1 (hr) | 2008-03-04 | 2015-08-11 | Farmaceutski pripravak zasnovan na lijeku za zaštitu jetre i prebiotiku, proizvodnja i njegova uporaba |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9446058B2 (hr) |
| EP (1) | EP2266619B1 (hr) |
| CN (1) | CN102014960A (hr) |
| BR (1) | BRPI0822449A2 (hr) |
| CY (1) | CY1116601T1 (hr) |
| DK (1) | DK2266619T3 (hr) |
| EA (1) | EA019985B1 (hr) |
| ES (1) | ES2545105T3 (hr) |
| HR (1) | HRP20150849T1 (hr) |
| PL (1) | PL2266619T3 (hr) |
| SI (1) | SI2266619T1 (hr) |
| WO (1) | WO2009110816A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013103250A1 (ko) * | 2012-01-06 | 2013-07-11 | 주식회사 대웅제약 | 타우로우루소데옥시콜릭산을 포함하는 조성물 |
| CA3050535C (en) | 2014-12-15 | 2021-11-09 | Richard Clark Kaufman | Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of anti-inflammatory nutraceuticals |
| CN106509889A (zh) * | 2016-11-04 | 2017-03-22 | 山东维尼莱生物科技股份有限公司 | 一种对酒精性肝损伤有辅助保护作用的保健品 |
| JP6772773B2 (ja) * | 2016-11-14 | 2020-10-21 | ブラザー工業株式会社 | 通信装置 |
| CN111494333B (zh) * | 2020-04-14 | 2022-06-14 | 安士制药（中山）有限公司 | 一种熊去氧胆酸胶囊及其制备方法 |
| EP4147706A1 (en) * | 2020-05-05 | 2023-03-15 | Abou Nehmi Filho, Victor | Composition for regulating the neuro-immune-endocrine system |
| CN115040545A (zh) * | 2022-06-13 | 2022-09-13 | 江南大学 | 鸡胆粉在制备解酒护肝药物中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1283225B1 (it) * | 1996-03-11 | 1998-04-16 | Renata Maria Anna Ve Cavaliere | Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle |
| EP1255566A2 (en) | 2000-02-04 | 2002-11-13 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| JP3908513B2 (ja) | 2001-11-19 | 2007-04-25 | 日本甜菜製糖株式会社 | 肝機能改善剤 |
| RU2205637C1 (ru) * | 2002-04-24 | 2003-06-10 | Закрытое акционерное общество "Брынцалов-А" | Гепатопротекторное средство "карсилин" |
| BG108250U (en) | 2003-10-10 | 2005-04-30 | "Софарма" Ад | Probiotic food additive |
| CZ20033042A3 (cs) * | 2003-11-10 | 2005-06-15 | Naturprodukt Cz Spol. S R. O. | Potravinový doplněk na bázi silymarinu |
| HUP0500582A1 (hu) * | 2005-06-13 | 2007-08-28 | Csaba Jozsef Dr Jaszberenyi | Szinergetikus élettani hatású élelmiszerek, élelmiszer-adalékok és táplálék-kiegészítõk vagy takarmányadalékok |
| RU2310463C1 (ru) * | 2006-05-19 | 2007-11-20 | Закрытое акционерное общество "Партнер" | Гепатопротекторный пробиотик |
-
2008
- 2008-03-04 EP EP08873197.1A patent/EP2266619B1/de active Active
- 2008-03-04 EA EA201001100A patent/EA019985B1/ru not_active IP Right Cessation
- 2008-03-04 ES ES08873197.1T patent/ES2545105T3/es active Active
- 2008-03-04 DK DK08873197.1T patent/DK2266619T3/en active
- 2008-03-04 BR BRPI0822449-8A patent/BRPI0822449A2/pt not_active IP Right Cessation
- 2008-03-04 WO PCT/RU2008/000122 patent/WO2009110816A1/ru active Application Filing
- 2008-03-04 SI SI200831478T patent/SI2266619T1/sl unknown
- 2008-03-04 US US12/921,383 patent/US9446058B2/en active Active
- 2008-03-04 CN CN2008801288413A patent/CN102014960A/zh active Pending
- 2008-03-04 PL PL08873197T patent/PL2266619T3/pl unknown
-
2015
- 2015-08-11 CY CY20151100705T patent/CY1116601T1/el unknown
- 2015-08-11 HR HRP20150849TT patent/HRP20150849T1/hr unknown
-
2016
- 2016-08-18 US US15/240,249 patent/US20160354387A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2545105T3 (es) | 2015-09-08 |
| US20110312910A1 (en) | 2011-12-22 |
| US9446058B2 (en) | 2016-09-20 |
| EA201001100A1 (ru) | 2011-02-28 |
| CN102014960A (zh) | 2011-04-13 |
| DK2266619T3 (en) | 2015-08-24 |
| PL2266619T3 (pl) | 2015-10-30 |
| WO2009110816A1 (ru) | 2009-09-11 |
| SI2266619T1 (sl) | 2015-11-30 |
| EP2266619A4 (de) | 2011-07-20 |
| EA019985B1 (ru) | 2014-07-30 |
| BRPI0822449A2 (pt) | 2015-06-16 |
| CY1116601T1 (el) | 2017-03-15 |
| US20160354387A1 (en) | 2016-12-08 |
| EP2266619B1 (de) | 2015-05-13 |
| EP2266619A1 (de) | 2010-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150849T1 (hr) | Farmaceutski pripravak zasnovan na lijeku za zaštitu jetre i prebiotiku, proizvodnja i njegova uporaba | |
| Jiang et al. | Current developments in pharmacological therapeutics for chronic constipation | |
| ES2325589T3 (es) | Combinacion farmaceutica de etinilestradiol y drospirenona para uso como anticonceptivo. | |
| JP2013529665A5 (hr) | ||
| WO2012013495A1 (en) | Pharmaceutical and/or dietary compositions based on short chain fatty acids | |
| CN101048164B (zh) | 降低肌萎缩性侧索硬化中神经变性的组合物 | |
| CN103038245A (zh) | 作为hiv成熟抑制剂的c-3经修饰的桦木酸衍生物 | |
| WO2007144152A2 (en) | Extended step-down estrogen regimen | |
| NZ605176A (en) | Pharmaceutical composition comprising drospirenone and contraceptive kit | |
| HRP20240121T1 (hr) | Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine | |
| JP2021088575A (ja) | Ｇｉ管障害を治療するための方法 | |
| JP2018527305A5 (hr) | ||
| US20110046080A1 (en) | Composition for Treating a Skin Disorder | |
| KR20180094950A (ko) | 간내 담즙정체증 및 관련 간 질환들의 치료 | |
| RU2014140177A (ru) | Фармацевтические антиретровирусные композиции | |
| EP2968364A1 (en) | Onapristone polymorphic forms and methods of use | |
| ES2641143T3 (es) | Una composición farmacéutica que comprende palmitoiletanolamida y citidina-difosfocolina | |
| JP2021504370A5 (hr) | ||
| DE19849737A1 (de) | Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen | |
| ES2262655T3 (es) | Nuevos compuestos cristalinos que comprenden fitosteroles y fitostanoles o sus derivados. | |
| CA2395446A1 (en) | Compositions, kits, and methods for cardiovascular health | |
| JP5371189B2 (ja) | 炎症性腸疾患の治療のためのシクレソニドの使用 | |
| WO2011100668A4 (en) | Methods and compositions of civamide to treat diseases of the intestines | |
| EP3461485A1 (en) | Use of nor-ursodeoxycholic acid for reducing liver fat | |
| CN102342955A (zh) | 一种治疗高磷血症的药物组合物及其制剂 |